| Literature DB >> 33923513 |
Mohamed A Hashem1, Noura A Abd-Allah1, Essam A Mahmoud1, Shimaa A Amer2, Mohamed Alkafafy3.
Abstract
The aim of this study is to assess the efficiency of psyllium husk ethanolic extract (PHEE) on Triton X-100 induced hyperlipidemic rats by studying the changes in hepatic and pancreatic function and histopathology. Forty male albino rats (bodyweight 175-188 g) were grouped randomly into four sets with ten rats. The experimental groups included: (1) control group (CON); (2) Triton X-100 induced hyperlipidemic group-rats were intraperitoneally injected with a single dose of Triton X-100 (100 mg/kg body weight) on the 21st day of Trial onset; (3) PHEE group-PHEE was orally administered (100 mg/kg body weight dissolved in 1 mL of distilled water) by gastric tube from the first day of the experiment until the fortieth day, once daily, (PHEE); (4) PHEE +Triton group, which received PHEE orally with the induction of hyperlipidemia. Treating hyperlipidemic rats with PHEE showed a decrease in the total serum lipids, triglyceride (TG), total cholesterol (TC), atherogenic index (AI), and malondialdehyde (MDA) with an increase in superoxide dismutase (SOD) and catalase (CAT) activities. PHEE administration alleviated the negative impact of Triton on the serum levels of glucose, insulin, glycated hemoglobin (HbA1c), homeostatic model assessment for insulin resistance (HOMA IR index), leptin hormone, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma-Glutamyl Transferase (GGT) and proteinogram. The Triton-induced hyperlipidemic rats showed extensive histopathological changes in the liver and pancreas, which were alleviated with PHEE administration. It could be concluded that PHEE has potent effects against hyperlipidemia, hyperglycemia, and oxidative stress due to its biologically active constituents detected by GC-MS analysis. This study's findings may help develop a novel trial against the effects of hyperlipidemia in the future.Entities:
Keywords: Triton X-100; antioxidants; hyperlipidemia; leptin; psyllium husk ethanolic extract
Year: 2021 PMID: 33923513 PMCID: PMC8074146 DOI: 10.3390/biology10040335
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
The identified compounds of PHEE by GC-MS analysis.
| No | Retention Time (min) | The Chemical Name of the Compound | Molecular Formula | Peak Area (%) |
|---|---|---|---|---|
| 1 | 17.82 | DL-Arabinose 2,3,4,5-Tetrahydroxypentanal | C5H10O5 | 27.21 |
| 2 | 29.21 | D-Xylose | C5H10O5 | 13.80 |
| 3 | 29.10 | Ethyl 9.cis.,11. trans.-octadecadienoate | C20H36O2 | 11.95 |
| 4 | 27.89 | 9,12-Octadecadienoic Acid, Methyl Ester, (E, E) | C19H34O2 | 11.86 |
| 5 | 28.01 | 9-Octadecenoic acid, methyl ester, (E)- | C19H36O2 | 5.85 |
| 6 | 26.06 | Myristicin | C11H12O3 | 4.15 |
| 7 | 19.87 | 9,12,15-Octadecatrienoic acid, 2,3-bis [(trimethylsilyl)oxy]propyl ester, (Z,Z,Z)- | C27H52O4Si2 | 3.35 |
| 8 | 24.75 | Hexadecanoic acid, methyl ester | C17H34O2 | 2.94 |
| 9 | 11.18 | 2-Methoxy-4-Vinylphenol | C9H10O2 | 2.91 |
| 10 | 19.47 | β-Sitosterol | C29H50O | 2.57 |
| 11 | 18.77 | 7a,12a-Dihydroxy-cholestene-3-one | C27H44O3 | 2.22 |
| 12 | 16.04 | Undecane | C11H18O | 2.13 |
| 13 | 29.67 | Pentacosane | C25H52 | 2.04 |
| 14 | 18.90 | Dodecamethyle cyclohexasiloxane | C12H36O6 | 2.01 |
| 15 | 19.30 | Stigmata-4-en-3-one | C29H48O | 1.91 |
| 16 | 18.01 | 3,7,11,15,18-Pentaoxa-2,19-disilaeicosane, 2,2,19,19-tetramethyl | C17H40O5 | 1.89 |
| 17 | 19.41 | Ar-turmerone | C15H20O | 1.20 |
Changes in lipogram and atherogenic index (mean value ±SE).
| CON | Triton | PHEE | PHEE + Triton | F. Test | |
|---|---|---|---|---|---|
| Total lipids (mg/dL) | 624.60 c ± 0.30 | 750.40 a ± 0.67 | 608.80 c ± 0.91 | 690.80 b ± 0.38 | ** |
| Cholesterol(mg/dL) | 180.40 c ± 0.61 | 266 a ± 0.40 | 177.60 c ± 0.22 | 202.20 b ± 0.44 | ** |
| TG (mg/dL) | 110.20 c ± 0.47 | 164.40 a ± 0.50 | 109.80 c ± 0.54 | 115.40 b ± 0.61 | ** |
| HDL-c (mg/dL) | 63.60 a ± 0.69 | 42 c ± 0.32 | 64 a ± 0.80 | 64.20 b ± 0.28 | ** |
| LDL-c (mg/dL) | 94.76 c ± 0.67 | 191.12 a ± 0.18 | 91.64 c ± 0.42 | 109.32 b ± 0.72 | ** |
| VLDL-c (mg/dL) | 22.04 c ± 0.49 | 32.88 a ± 0.99 | 21.96 c ± 1.10 | 23.08 b ± 0.52 | ** |
| Atherogenic index | 0.239 c ± 0.013 | 0.600 a ± 0.035 | 0.235 c ± 0.032 | 0.254 b ± 0.017 | ** |
a, b, c Means within the same column having different superscript letters were significantly different. ** significant at p ≤ 0.01.
Changes in some pancreatic function tests, serum leptin, and adiponectin hormones (mean value ± SE).
| CON | Triton | PHEE | PHEE + Triton | F. Test | |
|---|---|---|---|---|---|
| Serum Glucose (mg/dL) | 90.84 c ± 0.38 | 193 a ± 0.25 | 90.64 c ± 3.09 | 112.60 b ± 0.86 | ** |
| Insulin (nIU/mL) | 11.68 c ± 0.34 | 22.12 a ± 0.94 | 10.07 c ± 0.89 | 16.10 b ± 1.75 | ** |
| Hb-A1-c (ng/mL) | 1.60 c ± 0.03 | 6.19 a ± 0.35 | 1.53 c ± 0.10 | 3.04 b ± 0.35 | ** |
| Leptin (ng/mL) | 2.01 c ± 0.09 | 10.05 a ± 0.71 | 2.06 c ± 0.21 | 4.12 b ± 0.60 | ** |
| HOMA-IR | 2.60 c ± 0.07 | 10.56 a ± 0.68 | 2.38 c ± 0.14 | 4.56 b ± 0.63 | ** |
| Adiponectin (pg/mL) | 53.53 a ± 1.6 | 27.76 c ± 1.7 | 55 a ± 0.18 | 41.23 b ± 1.69 | ** |
a, b, c Means within the same column having different superscript letters were significantly different. ** significant at p ≤ 0.01.
Changes in liver function tests (mean value ±SE).
| CON | Triton | PHEE | PHEE + Triton | F. Test | |
|---|---|---|---|---|---|
| ALT(U/l) | 46.40 c ± 1.86 | 86.80 a ± 2.72 | 45.40 c ± 2.24 | 59.33 b ± 0.98 | ** |
| AST(U/l) | 28.00 c ± 0.54 | 49.20 a ± 0.86 | 27.20 c ± 2.37 | 34.50 b ± 0.99 | ** |
| GGT(U/l) | 25.80 c ± 1.52 | 52.20 a ± 2.08 | 28.80 c ± 2.35 | 40.33 b ± 2.43 | ** |
| Total protein (U/l) | 7.28 a ± 0.09 | 3.94 c ± 0.14 | 7.41 a ± 0.14 | 6.31 b ± 0.18 | ** |
| Albumin (U/l) | 3.89 a ± 0.09 | 1.78 c ± 0.10 | 4.11 a ± 0.10 | 3.29 b ± 0.14 | ** |
| Globulin (U/l) | 3.39 a ± 0.12 | 2.16 c ± 0.15 | 3.29 a ± 0.23 | 3.02 b ± 0.22 | ** |
| A/G (U/l) | 1.15 a ± 0.06 | 1.82 c ± 0.03 | 1.24 a ± 0.13 | 1.08 b ± 0.15 | ** |
a, b, c Means within the same column having different superscript letters were significantly different. ** significant at p ≤ 0.01.
Changes in serum lipid peroxidation and antioxidant enzyme activity (mean value ± SE).
| CON | Triton | PHEE | PHEE + Triton | F. Test | |
|---|---|---|---|---|---|
| MDA (nmol/mL) | 11.40 c ± 0.92 | 27.00 a ± 1.64 | 11.40 c ± 1.36 | 17.00 b ± 1.92 | ** |
| GSH (mmol/l) | 2.55 a ± 2.47 | 1.22 c ± 1.16 | 2.54 a ± 2.41 | 2.23 b ± 1.87 | ** |
| CAT U/l) | 166.40 a ± 2.08 | 123.20 c ± 3.33 | 165.80 a ± 3.35 | 149.00 b ± 3.76 | ** |
a, b, c Means within the same column having different superscript letters were significantly different. ** significant at p ≤ 0.01.
Figure 1Photomicrograph of H & E stained liver section of different groups. (A) The liver of normal control rats showing normal hepatic parenchyma (arrow) (×400). (B) Hyperlipidemic rats showing intense peripherlobular microsteatosis (arrow) and acute cell swelling in the remaining hepatic cells (×100). (C) The liver of rats administered with psyllium extract showing only hyperplastic Kupfer cells (arrowhead) and mild fibroblastic proliferation in the portal area (arrow). (×400). (D) Liver of hyperlipidemic rats treated with psyllium extract showing mild microsteatosis (arrow) in peripherlobular patterns of the hepatic lobules and normal remaining hepatic cells. (×100).
Figure 2Photomicrograph of H & E stained pancreas section of different groups. (A) The pancreas of normal control rats showing normal endocrine (arrow) and exocrine portions (arrowhead) (×100). (B) The pancreas of hyperlipidemic rats showing focal replacement of pancreatic acini with edematous fibrous tissue containing round cells and granulocytes (arrow) (×400). (C) The pancreas of rats administered with psyllium extract only showing normal endocrine (arrow) and exocrine pancreas (arrowhead) (×400). (D) The pancreas of hyperlipidemic rats treated with Psyllium showing hypertrophied endocrine (arrow) and active exocrine (arrowhead) (×400).